New York State Common Retirement Fund’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$472K Buy
69,300
+1,800
+3% +$10.7K ﹤0.01% 2021
2026
Q1
$302K Hold
67,500
﹤0.01% 2083
2025
Q4
$371K Sell
67,500
-100
-0.1% -$486 ﹤0.01% 2070
2025
Q3
$221K Buy
67,600
+46,500
+220% +$132K ﹤0.01% 2248
2025
Q2
$48.7K Hold
21,100
﹤0.01% 2951
2025
Q1
$29.3K Hold
21,100
﹤0.01% 2913
2024
Q4
$36.5K Hold
21,100
﹤0.01% 2938
2024
Q3
$42.4K Sell
21,100
-43,700
-67% -$95.9K ﹤0.01% 2911
2024
Q2
$145K Buy
+64,800
New +$189K ﹤0.01% 2571
2022
Q3
Sell
-191
Closed -$1K 3448
2022
Q2
$1K Sell
191
-14,100
-99% -$55.9K ﹤0.01% 3413
2022
Q1
$93K Buy
14,291
+4
+0% +$30 ﹤0.01% 3037
2021
Q4
$166K Sell
14,287
-40
-0.3% -$603 ﹤0.01% 2941
2021
Q3
$267K Sell
14,327
-4,847
-25% -$92.1K ﹤0.01% 2787
2021
Q2
$406K Buy
19,174
+10,374
+118% +$239K ﹤0.01% 2709
2021
Q1
$179K Buy
8,800
+3,900
+80% +$106K ﹤0.01% 2881
2020
Q4
$130K Buy
+4,900
New +$106K ﹤0.01% 2915

Other funds holding TSHA

New York State Common Retirement Fund's TSHA Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Taysha Gene Therapies (TSHA) stake by 2.7% in Q2 2026, buying an estimated $10.7K and bringing the position to 69,300 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #2021.

New York State Common Retirement Fund first reported a position in TSHA in Q4 2020 and has held it in 16 quarters since. 46 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • New York State Common Retirement Fund held 69,300 shares of Taysha Gene Therapies worth $472K as of Q2 2026.
  • New York State Common Retirement Fund bought 1,800 Taysha Gene Therapies shares in Q2 2026, an estimated $10.7K.
  • Taysha Gene Therapies made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #2021 holding.
  • New York State Common Retirement Fund first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 16 quarters since.
  • 46 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.